Sort
10,766 grants matching “checkpoint inhibitor”
Defining critical p53 therapeutic targets and mechanisms
$381,215Clodagh O'Shea · Salk Institute For Biological Studies · R01 · FY2012 · CA
Defining critical p53 therapeutic targets and mechanisms
$381,215Clodagh O'Shea · Salk Institute For Biological Studies · R01 · FY2011 · CA
Ciprofloxacin enhances DNA repair capacity after radiation combined injury
$381,173Juliann Gong Kiang · Henry M. Jackson Fdn For The Adv Mil/Med · R33 · FY2010 · AI
Chemical Genetic and Biochemical Studies of Mitotic Proteolysis
$381,157Randall W King · Harvard Medical School · R01 · FY2013 · GM
Study of the IL-33-driven immune cell organization underpinning responses to immune checkpoint blockade cancer therapy
$381,058Binfeng Lu · Hackensack University Medical Center · R01 · FY2024 · CA
Immune Regulation of Lung Squamous Metastasis
$381,053Chad V Pecot · Univ Of North Carolina Chapel Hill · R01 · FY2019 · CA
Imaging tumor associated macrophage (TAM) function
$380,871Ralph Weissleder · Massachusetts General Hospital · R01 · FY2021 · CA
Imaging tumor associated macrophage (TAM) function
$380,871Ralph Weissleder · Massachusetts General Hospital · R01 · FY2020 · CA
Regulation of Tumor Microenvironment in Cancer
$380,866Dmitry Isaac Gabrilovich · Wistar Institute · R01 · FY2016 · CA
Mechanisms of Intestinal Tumorigenesis
$380,854Vincent W. Yang · Emory University · R01 · FY2011 · CA
Shifting the balance between IFN-I and TGF-beta to improve cancer therapy
$380,847Mark W Jackson · Cleveland Clinic Lerner Com-Cwru · P01 · FY2024 · CA
Core C: Patient Derived Xenograft (PDX)/ Syngeneic Mouse Core
$380,670Gatien Moriceau · University Of California Los Angeles · P01 · FY2023 · CA
Core C: Patient Derived Xenograft (PDX)/ Syngeneic Mouse Core
$380,670Gatien Moriceau · University Of California Los Angeles · P01 · FY2022 · CA
Abbreviated targeted therapy to improve anti-PD-1 inhibitor efficacy in melanoma
$380,627Ryan J Sullivan · Massachusetts General Hospital · R01 · FY2021 · CA
Targeting interplay between KLF4 and PRMT5 in carcinogenesis
$380,585Yong Wan · University Of Pittsburgh At Pittsburgh · R01 · FY2016 · CA
Project 1: Promoting Graft-versus-Tumor Effects in the Bone Marrow
$380,582Geoffrey Roger Hill · Fred Hutchinson Cancer Research Center · P01 · FY2021 · CA
Abbreviated targeted therapy to improve anti-PD-1 inhibitor efficacy in melanoma
$380,517Ryan J Sullivan · Massachusetts General Hospital · R01 · FY2020 · CA
Mechanisms of liver metastasis and associated resistance to immunotherapy
$380,509Benjamin Izar · Columbia University Health Sciences · R37 · FY2021 · CA
Targeting immunosuppressive adenosine in patients with metastatic non-small cell lung cancer
$380,473David P Carbone · Ohio State University · R01 · FY2023 · CA
Role of microbial-modulated bile acid receptor signaling in breast cancer
$380,449Liza Makowski Hayes · University Of Tennessee Health Sci Ctr · R01 · FY2024 · CA
E2A AS A POTENTIAL TUMOR SUPPRESSOR
$380,441Cornelis Murre · University Of California, San Diego · R01 · FY2007 · CA
Mechanisms Governing Expansion of Embryonic Progenitor Cells (EPCs) inMetaplasia
$380,436Jason C Mills · Baylor College Of Medicine · R01 · FY2024 · CA
MOLECULAR CARCINOGENESIS IN THE MOUSE AND HUMAN PROSTATE
$380,335Pier Paolo Pandolfi · Sloan-Kettering Inst Can Research · P50 · FY2008 · CA
New Strategies for Treatment of NRAS Mutant Melanoma after Progression on Immune Checkpoint Inhibitors
$380,325Ann Richmond · Vanderbilt University · R01 · FY2023 · CA
Mechanisms of Intestinal Tumorigenesis
$380,306Vincent W. Yang · State University New York Stony Brook · R01 · FY2012 · CA